GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Trump discusses land swaps for peace between Ukraine and Russia - Global Banking & Finance Review
Image depicting Donald Trump announcing his proposal for land swaps to achieve peace between Ukraine and Russia, amidst ongoing conflict. This moment highlights his diplomatic approach to resolving tensions in Eastern Europe.
Finance

CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis

Published by Global Banking & Finance Review

Posted on October 5, 2026

2 min read

· Last updated: October 5, 2026

Add as preferred source on Google

CSL and Alentis Forge $1.6 Billion Deal for Rare Disease Drug Development

By Rajasik Mukherjee

CSL and Alentis Therapeutics Partnership Overview

Deal Structure and Financial Details

Oct 5 (Reuters) - Australia's CSL said on Monday it had entered into an agreement with Swiss drugmaker Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases, in a deal worth up to $1.6 billion, excluding development funding.

Under the partnership, CSL will make an upfront payment of $355 million, while Alentis is eligible for up to $1.2 billion in commercial milestone payments.

Market Reaction

CSL shares rose as much as 1.3% to A$177.550, while the broader benchmark ASX 200 index was up 0.6% as of 0005 GMT.

Lixudebart: The Rare Disease Drug Candidate

Development and Clinical Trials

The deal gives the Australian biotech giant rights to jointly develop and commercialise lixudebart, a potential first-in-class treatment being studied for rare kidney and liver diseases.

Lixudebart, formerly known as ALE.F02, is currently in a Phase 2 trial for a rare autoimmune kidney disease that can cause irreversible kidney damage and end-stage renal disease.

Regulatory Status

The US Food and Drug Administration granted the drug orphan status in 2024, which is intended to encourage development of treatments for rare diseases.  

Profit Sharing Agreement

Once commercialised, global profits from the drug will be shared 55% to CSL and 45% to Alentis.

Market and Analyst Perspectives

Analyst Commentary

"The markets are treating this as good news, but not enough on its own to change the fortunes of the company," said Kyle Rodda, a senior financial market ​analyst at Capital.com.

"Although this news creates upside risks to future earnings, it's probably not enough to improve the company's long-term growth outlook."

CSL's Recent Business Challenges

CSL, once Australia's most valuable listed company, has faced investor pressure in recent months after unveiling plans to cut up to 3,000 jobs, downgrading earnings guidance, and delaying the spin-off of its Seqirus vaccines business.

Early this year, the CSL stock hit its lowest level since 2017 after the US Pentagon's decision to scrap a flu-shot mandate for military personnel added to concerns about growth prospects and demand for its vaccines business.

(Reporting by Rajasik Mukherjee in Bengaluru; Editing by Nia Williams and Rashmi Aich)

Key Takeaways

  • CSL will pay US$355 million upfront and could pay up to US$1.2 billion more in commercial milestones, excluding development funding (live.euronext.com)
  • Lixudebart (formerly ALE.F02) is in Phase 2 trials for rare autoimmune kidney (AAV‑RPGN) and liver diseases (FSGS, PSC), with FDA orphan designation granted in 2024 (live.euronext.com)
  • Profits, if the drug is commercialised, will be shared 55% to CSL and 45% to Alentis; CSL will fund remaining development including Phase 3 trials (prnewswire.com)

References

Frequently Asked Questions

What is the total potential value of the CSL and Alentis deal?
The CSL and Alentis partnership deal is worth up to $1.6 billion, excluding development funding.
What drug are CSL and Alentis co-developing?
CSL and Alentis are co-developing lixudebart, a potential first-in-class treatment for rare kidney and liver diseases.
What stage is lixudebart currently in?
Lixudebart is currently in a Phase 2 trial for a rare autoimmune kidney disease.
How will profits from the commercialised drug be shared?
Profits will be shared globally, with CSL receiving 55% and Alentis 45%.
Why did CSL stock rise after this announcement?
CSL shares rose as the deal was viewed positively by markets, offering upside risks to future earnings.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category